多基因检测时代来临？Oncotype DX和MammaPrint的临床应用价值
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
作者信息
Xin Ling, Liu Yin-Hua, Martin Tracey A, Jiang Wen G
机构信息
Department of Breast Disease, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing 100034, China.
Cardiff China Medical Research Collaborative (CCMRC), School of Medicine, Cardiff University, Ground Floor, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK.
出版信息
World J Oncol. 2017 Apr;8(2):34-40. doi: 10.14740/wjon1019w. Epub 2017 May 4.
Abstract
The AJCC Cancer Staging Manual, eighth edition published in late 2016, will become the new global guideline for cancer diagnosis and treatment from January 1, 2018. The new edition for the tumor staging system has numerous updates, including building up the prognostic stage group of tumors for the first time and adding a large number of non-anatomical factors into the prognostic evaluation. Oncotype DX and MammaPrint are two of the genomic predictors that will be part of routine clinical practice in the future. Numerous studies have proved the clinical utility of multigene panels in predicting clinical outcome and treatment response. Here we present our review of the studies on these multigene panels and their application to breast cancer.
摘要
2016年末出版的《美国癌症联合委员会（AJCC）癌症分期手册》第八版将于2018年1月1日起成为全球癌症诊断与治疗的新指南。新版肿瘤分期系统有诸多更新，包括首次构建肿瘤的预后分期组，并在预后评估中纳入大量非解剖学因素。Oncotype DX和MammaPrint是两种基因组预测指标，未来将成为常规临床实践的一部分。大量研究已证实多基因检测板在预测临床结局和治疗反应方面的临床实用性。在此，我们对这些多基因检测板的相关研究及其在乳腺癌中的应用进行综述。
相似文献
1
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
World J Oncol. 2017 Apr;8(2):34-40. doi: 10.14740/wjon1019w. Epub 2017 May 4.
2
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Jul 8;67(4):290-303. doi: 10.3322/caac.21393. Epub 2017 Mar 14.
3
Clinical utility of multigene profiling assays in early-stage breast cancer.
Curr Oncol. 2017 Oct;24(5):e403-e422. doi: 10.3747/co.24.3595. Epub 2017 Oct 25.
4
Multigene Signature Panels and Breast Cancer Therapy: Patterns of Use and Impact on Clinical Decision Making.
J Am Coll Surg. 2018 Apr;226(4):406-412.e1. doi: 10.1016/j.jamcollsurg.2017.12.043. Epub 2018 Jan 31.
5
The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
Pathobiology. 2019;86(2-3):77-82. doi: 10.1159/000493363. Epub 2018 Oct 22.
6
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf.
8
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Radiology. 2016 Nov;281(2):382-391. doi: 10.1148/radiol.2016152110. Epub 2016 May 5.
9
Application Of Multigene Panel Detection In Breast Cancer.
J Pak Med Assoc. 2023 Sep;73(9):1862-1868. doi: 10.47391/JPMA.6830.
10
American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know.
Radiographics. 2018 Nov-Dec;38(7):1921-1933. doi: 10.1148/rg.2018180056. Epub 2018 Sep 28.
引用本文的文献
1
A lipid metabolism-related gene signature predicts prognosis after tamoxifen treatment in ER + breast cancer and reflects tumor microenvironment heterogeneity through single-cell analysis.
BMC Med Genomics. 2025 Jul 31;18(1):123. doi: 10.1186/s12920-025-02194-5.
2
Deep learning predicts the effect of neoadjuvant chemotherapy for patients with triple negative breast cancer.
J Pathol Inform. 2025 May 14;18:100448. doi: 10.1016/j.jpi.2025.100448. eCollection 2025 Aug.
3
Systematic Modeling of Risk-Associated Copy Number Alterations in Cancer.
Int J Mol Sci. 2024 Sep 27;25(19):10455. doi: 10.3390/ijms251910455.
4
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
Breast Cancer Res Treat. 2025 Jan;209(1):189-199. doi: 10.1007/s10549-024-07486-5. Epub 2024 Oct 4.
5
The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer.
Int J Mol Sci. 2024 Jul 24;25(15):8077. doi: 10.3390/ijms25158077.
6
Integrated single-cell and bulk RNA sequencing revealed an epigenetic signature predicts prognosis and tumor microenvironment colorectal cancer heterogeneity.
World J Gastrointest Oncol. 2024 Jul 15;16(7):3032-3054. doi: 10.4251/wjgo.v16.i7.3032.
7
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine.
J Pers Med. 2024 Jul 3;14(7):719. doi: 10.3390/jpm14070719.
8
MicroRNA as a promising molecular biomarker in the diagnosis of breast cancer.
Front Mol Biosci. 2024 May 15;11:1337706. doi: 10.3389/fmolb.2024.1337706. eCollection 2024.
9
Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Int J Mol Sci. 2024 Mar 28;25(7):3780. doi: 10.3390/ijms25073780.
10
Systematic Characterization of p53-Regulated Long Noncoding RNAs across Human Cancers Reveals Remarkable Heterogeneity among Different Tumor Types.
Mol Cancer Res. 2024 Jun 4;22(6):555-571. doi: 10.1158/1541-7786.MCR-23-0295.
本文引用的文献
1
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
J Natl Compr Canc Netw. 2017 Mar;15(3):346-354. doi: 10.6004/jnccn.2017.0034.
2
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Eur J Cancer. 2017 Apr;75:284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
3
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
J Natl Cancer Inst. 2017 Jan 25;109(4). doi: 10.1093/jnci/djw259. Print 2017 Jan.
4
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Eur J Surg Oncol. 2017 May;43(5):931-937. doi: 10.1016/j.ejso.2016.12.010. Epub 2017 Jan 9.
5
Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX Breast Recurrence Score Assay.
Eur J Surg Oncol. 2017 May;43(5):921-930. doi: 10.1016/j.ejso.2016.11.016. Epub 2016 Dec 14.
6
Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
Eur J Surg Oncol. 2017 May;43(5):909-920. doi: 10.1016/j.ejso.2016.08.012. Epub 2016 Aug 31.
7
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
8
Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis.
Oncol Res Treat. 2016;39(3):102-10. doi: 10.1159/000444409. Epub 2016 Feb 24.
9
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.
10
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8.
Zotero 插件